Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN signed an exclusive license agreement worth up to USD 365M (approx. KRW 521.9B) to develop and commercialize a subcutaneous (SC) formulation for one target product using its recombinant human hyaluronidase platform (ALT-B4). 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key Follow-up…

Read More “[Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Following its bonus issue, an ex-rights adjustment for ALTEOGEN common stock will take effect on August 5, 2026, with an ex-rights base price set at KRW 267,000. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Ex-Rights Base…

Read More “[Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Korea Exchange (KRX) will adjust base prices, trading multipliers (12.99867263), and strike prices for ALTEOGEN stock futures and options effective August 5, 2026, and delist certain futures spread contracts following the company’s bonus issue. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key…

Read More “[Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has submitted an application to the Ministry of Food and Drug Safety (MFDS) to modify its Phase 3 clinical trial plan in South Korea for CT-P44, a biosimilar to Darzalex (a treatment for multiple myeloma). The amendment involves adjusting the number of clinical trial participants…

Read More “[Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for CT-P55, a biosimilar to Cosentyx (a treatment for autoimmune diseases). Based on the clinical data obtained, the company is seeking approval for six indications, including plaque psoriasis. 📊 [Summary…

Read More “[Disclosure] Celltrion (068270) – CT-P55 (Cosentyx Biosimilar) U.S. BLA Submission / 2026-07-30” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has issued a correction to its Q2 2026 provisional financial results. Compared to the initial disclosure, the Q2 consolidated revenue has been revised upward to KRW 1.3937T and operating profit to KRW 451.8B. 📊 [Summary of Key Disclosure Content & Major Figures] [Corrections in Q2…

Read More “[Disclosure] Celltrion (068270) – (Correction) Provisional Consolidated Financial Results / 2026-07-27” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has submitted a Marketing Authorization Application to the European Medicines Agency (EMA) and the European Commission (EC) for CT-P55, a biosimilar to Cosentyx (a treatment for autoimmune diseases). Based on the clinical data obtained, the company is seeking approval for all full adult and pediatric…

Read More “[Disclosure] Celltrion (068270) – CT-P55 (Cosentyx Biosimilar) Europe Marketing Authorization Application / 2026-07-24” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has submitted an application for Part 1 & Part 2 of a Phase 3 clinical trial plan to the European Medicines Agency (EMA) for Zymfentra (CT-P13 SC) in patients with rheumatoid arthritis. The study aims to secure additional clinical data, including racial diversity and varied…

Read More “[Disclosure] Celltrion (068270) – CT-P13 SC (Zymfentra) Europe Phase 3 Clinical Trial Plan Application (Part 1 & 2) (Rheumatoid Arthritis Patients) / 2026-07-24” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has submitted an application to the U.S. Food and Drug Administration (FDA) for a Phase 3 clinical trial plan for Zymfentra (CT-P13 SC) in patients with rheumatoid arthritis. The trial aims to secure additional clinical data, including patient racial diversity and varied treatment histories. 📊…

Read More “[Disclosure] Celltrion (068270) – CT-P13 SC (Zymfentra) U.S. Phase 3 Clinical Trial Plan Application (Rheumatoid Arthritis Patients) / 2026-07-24” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has submitted an application to the Ministry of Food and Drug Safety (MFDS) for a Phase 3 clinical trial plan in South Korea for Zymfentra (CT-P13 SC) in patients with rheumatoid arthritis. The study aims to secure additional clinical data, including patient demographics and prior…

Read More “[Disclosure] Celltrion (068270) – CT-P13 SC (Zymfentra) Korea Phase 3 Clinical Trial Plan Application (Rheumatoid Arthritis Patients) / 2026-07-24” »